Mustang Bio (NASDAQ:MBIO) is a clinical-stage biopharmaceutical company focused on developing cell and gene therapies for oncology and rare genetic diseases. The company’s pipeline includes chimeric antigen receptor T-cell (CAR-T) candidates and adeno‐associated virus (AAV)–based gene therapies designed to address high unmet medical needs. Mustang Bio’s research efforts center on harnessing the body’s immune system to target and eradicate malignant or dysfunctional cells, as well as delivering corrective genetic material to restore or improve patient health in inherited disorders.
The company’s lead oncology candidate, MB-101, is a CAR-T therapy targeting interleukin-13 receptor alpha 2 (IL13Rα2) in glioblastoma multiforme. In parallel, Mustang Bio is advancing MB-102, an AAV-based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and MB-107, an AAV-based gene therapy for X-linked severe combined immunodeficiency (SCID-X1). These programs are supported by clinical collaborations with leading academic institutions and research centers, including partnerships to enhance manufacturing processes and accelerate regulatory filings.
Founded in 2015 and headquartered in Cambridge, Massachusetts, Mustang Bio operates facilities in both the United States and Europe to support its global development strategy. The company leverages its proprietary platform technologies and scalable manufacturing capabilities to advance multiple programs simultaneously, while maintaining regulatory interaction across North America and the European Union. Mustang Bio’s operations emphasize rigorous clinical trial design, patient safety, and data transparency to drive timely progress toward potential regulatory approvals.
Under the leadership of President and CEO Manuel Litchman, Ph.D., Mustang Bio is guided by a management team with extensive experience in biotech research, clinical development, and regulatory affairs. Co-founder and Chief Scientific Officer Guido Ferrari, M.D., Ph.D., spearheads the company’s R&D efforts, while Chief Medical Officer Scott Myers, M.D., oversees clinical strategy and trial execution. Mustang Bio’s leadership combines scientific expertise with strategic vision to advance transformative therapies from the laboratory to the clinic.
